NOVAVAX INC (NVAX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$232.9M
Cash & Equivalents
$32.4M
Quarterly Burn Rate
22 mo
Est. Cash Runway
$1,534M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-18 | Phase1 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07086222 | Efficacy and Safety of NVX-CoV2705 | PHASE4 | Active Not Recruiting | 6,500 |
| NCT03305341 | Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix | PHASE1 | Active Not Recruiting | 20 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.